Status:
COMPLETED
CemiplimAb Survivorship Epidemiology
Lead Sponsor:
Regeneron Pharmaceuticals
Conditions:
Cutaneous Squamous Cell Carcinoma
Basal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The objectives of the study are: * To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastat...
Eligibility Criteria
Inclusion
- Key
- Eligible for treatment with and prescribed cemiplimab for advanced CSCC or advanced BCC in accordance with approved prescribing information as described in the protocol
- Key
Exclusion
- Receiving cemiplimab for an indication other than advanced CSCC or advanced BCC
- Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study
- Patients concurrently participating in any study including administration of any investigational drug (including cemiplimab) or procedure (including survival follow up)
- Note: Other protocol defined Inclusion/Exclusion Criteria apply
Key Trial Info
Start Date :
June 27 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2025
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT03836105
Start Date
June 27 2019
End Date
September 29 2025
Last Update
October 15 2025
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Specialties, PC - Clearview Cancer Institute
Huntsville, Alabama, United States, 35805
2
Dignity Health St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States, 85013
3
CARTI Cancer Center
Little Rock, Arkansas, United States, 72205
4
University of California San Diego
La Jolla, California, United States, 92037